AKRIBES INNOVATION

AKRIBES PROPRIETARY „THERANOSTIC“ ASSAY PLATFORM

Patient-specific in vitro / ex vivo wound systems

Theranostic = therapy recommendation based on the analysis (diagnosis) of the wound
AKRIBES PROPRIETARY „THERANOSTIC“ ASSAY PLATFORM

ASSAY PLATFORM WITH WOUND-SPECIFIC CELL TYPES

ASSAY PLATFORM WITH WOUND-SPECIFIC CELL TYPES.

FIBROBLAST PROLIFERATION ASSAY:
MINIATURIZED ASSAY IN LAB-ON-A-CHIP FORMAT

There is a causal link between wound chronicity and detrimental effects of wound exudates on primary human fibroblasts.

Progression from a non-healing to a healing wound is linked with the restauration of proliferation and reduction of IL-1ß secretion.

Goal: To identify compounds which reverse the detrimental effects of chronic wound exudates on primary human cells.

NEW WOUND HEALING THERAPEUTICS

Patient-specific selection of the right drug

IDENTIFICATION OF A POTENTIAL WOUND HEALING THERAPEUTIC

Substance 1 rescues fibroblasts from wound fluid-induced damage

Quantification of the rescue-effect of substance 1 (readout from a plate reader)

AKRIBES PIPELINE

COLLABORATION & INVESTMENT OPPORTUNITIES

Innovation through Akribes assay platform

Innovation through development of new therapeutics

Copyright © 2021 - Akribes Biomedical GmbH